Daraxonrasib Shows 61% Response Rate in Metastatic Pancreatic Cancer

Early-stage trial results indicate daraxonrasib combined with chemotherapy could significantly improve outcomes for metastatic pancreatic cancer patients.

A
Aapla Nagpur Desk
21 Nov 2026, 1:46 AM IST · 2 min read
Source: Medpagetoday
Daraxonrasib Shows 61% Response Rate in Metastatic Pancreatic Cancer
KEY TAKEAWAYS
1

Daraxonrasib achieved a 61% objective response rate in a phase I/II trial.

2

Median progression-free survival was reported at 12.8 months.

3

The drug has received FDA approval for use in previously treated patients.

In a promising development for metastatic pancreatic adenocarcinoma (PDAC) treatment, the RAS inhibitor daraxonrasib, when combined with chemotherapy, demonstrated a confirmed objective response rate of 61% in an early-phase trial. The study, presented by Dr. Wungki Park at the EORTC-NCI-AACR Symposium in Barcelona, involved 61 patients and reported a complete response rate of 8.2%, with a median duration of response lasting 11.1 months.

The trial's results also highlighted a median progression-free survival (PFS) of 12.8 months, with a notable 12-month PFS rate of 51.7%. The overall survival (OS) rate at the 12-month mark reached 76.6%. Dr. Park emphasized that these findings could represent a significant advancement in first-line treatment options, surpassing the historical OS range of 8.5 to 11.1 months associated with conventional chemotherapy.

Experts, including Dr. Shivan Sivakumar from the University of Birmingham, expressed optimism about the results, noting that they could herald a shift away from traditional chemotherapy as the primary treatment for pancreatic cancer. By targeting RAS, a key driver in most pancreatic cancers, there is potential for molecularly targeted therapies to enhance patient outcomes significantly. However, Sivakumar advised caution, highlighting the study's small scale and lack of a randomized control group.

Daraxonrasib, an oral multi-selective RAS inhibitor, previously demonstrated its efficacy in a phase III trial, where it doubled OS and PFS for patients with previously treated metastatic PDAC. Following these results, the FDA approved the drug for patients who have undergone at least one prior systemic therapy. The ongoing RMC-GI-102 trial is further evaluating daraxonrasib among patients with RAS-mutant gastrointestinal tumors, with the current analysis focusing on its combination with gemcitabine and nab-paclitaxel.

The patient cohort in the trial had a median age of 67, with 59% being male. A significant portion of participants had advanced disease, with 70% exhibiting liver metastases at enrollment. While the treatment was associated with grade ≥3 adverse events in 75% of patients, the discontinuation rate due to these events was relatively low at 5%. As research continues, the upcoming phase III RASolute 303 trial will be crucial in confirming these early findings and potentially reshaping treatment protocols for metastatic pancreatic cancer.

💬What did you think of this story?What did you think?

Read Next